Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
FDA Requests More Data on Potential New Treatment for Huntington Disease
Teva takes on Neurocrine with TD nod for Austedo | Fierce Pharma
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers - Schneider - 2020 - Clinical and Translational Science - Wiley Online Library
AUSTEDO® (deutetrabenazine) tablets: Tardive Dyskinesia and Huntington's Chorea Treatment
Austedo - FDA prescribing information, side effects and uses
Teva announces FDA approval of Austedo tablets for chorea associated with huntington's disease - Pharma Advancement
Teva's Austedo Tablets for Chorea Treatment Approved - Drug Discovery and Development
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease - Chemdiv
Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® ( deutetrabenazine) tablets